http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Bile Acid Transporters Are Expressed and Heterogeneously Distributed in Rat Bile Ducts
Zhu-lin Luo,Long Cheng,Tao Wang,Li-jun Tang,Fu-zhou Tian,Ke Xiang,Lin Cui 거트앤리버 소화기연관학회협의회 2019 Gut and Liver Vol.13 No.5
Background/Aims: Cholangiocytes are capable of reabsorbing bile salts from bile, but the pathophysiological significance of this process is unclear. To this end, we detected the expression and distribution of bile acid transport proteins in cholangiocytes from normal rat liver and analyzed the possible pathophysiological significance. Methods: Bile duct tissues of Sprague-Dawley rats were isolated by enzymatic digestion and mechanical isolation, and then divided into large and small bile duct tissues. Immunohistochemistry, real-time polymerase chain reaction and Western blotting were used to determine the expression of the apical sodium-dependent bile acid transporter (ASBT), ileal bile acid binding protein (IBABP), and basolateral organic solute transporter α (Ostα) in the biliary tract system of rats. Differences in the expression and distribution of these proteins were analyzed. Results: In cholangiocytes, ASBT and IBABP were mainly expressed in cholangiocytes of the large bile ducts, in which the expression of both was significantly higher than that in the small ducts (p<0.05). Ostα was simultaneously expressed in cholangiocytes of both the large and small bile ducts, showing no significant difference in expression between the two groups of bile ducts (p>0.05). Conclusions: Bile acid transporters are expressed and heterogeneously distributed in rat bile ducts, indicating that bile acid reabsorption by cholangiocytes might mainly occur in the large bile ducts. These findings may help explore the physiology of bile ducts and the pathogenesis of various cholangiopathies.
Ying Xiong,Lisha Xie,Long Zhu,Yuejiao Wang,Weijun Shan,Zhenning Lou,Junshuo Cui,Haibiao Yu 한국공업화학회 2022 Journal of Industrial and Engineering Chemistry Vol.108 No.-
In this study, a three-dimensional chitosan/mesoporous silica composite material (I-CTS-KIT-6) was successfullysynthesized by one-step method using ion imprinting technology. To overcome the enormouscost problem, MoO4 2 with similar radius to ReO4was selected as template ion. In addition, the adsorbentwas prepared by using glutaraldehyde and chitosan as crosslinking agents and monomers and TEOS assilicon source in the process of imprinting. The effects of pH values, mass of chitosan and templateion, contact time, temperature and concentration on Re(VII) adsorption were studied. The resultsrevealed that the I-CTS-KIT-6 has the saturated adsorption capacity of 368.8 mg g1 at pH 3.0 for Re(VII), and the adsorption process corresponded to Langmuir isotherm and pseudo-second-order kinetics. Especially, the I-CTS-KIT-6 has higher selectivity for rhenium ions compared with the non-imprintedadsorbent. To verify the adsorption mechanism, density functional theory (DFT) was adopted to analyzethe binding patterns of Re(VII) with the I-CTS-KIT-6. The test analysis and calculation results further mentionedthat the adsorption mechanism is mainly three N atoms of I-CTS-KIT-6 coordinated with threeoxygen atoms of ReO4, which provides the theoretical foundations and explanations for adsorptionprocess.
Chen, Hai-Fei,Li, Zheng-Yang,Tang, Jie-Qing,Shen, Hong-Shi,Cui, Qing-Ya,Ren, Yong-Ya,Qin, Long-Mei,Jin, Ling-Juan,Zhu, Jing-Jing,Wang, Jing,Ding, Jie,Wang, Ke-Yuan,Yu, Zi-Qiang,Wang, Zhao-Yue,Wu, Tian Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.9
Objective: To investigate the relationship between the efficacy and safety of different doses of thalidomide (Thal) plus dexamethasone (Dex) as the initial therapy in elderly patients with newly diagnosed multiple myeloma (MM). Methods: Clinical data of 28 elderly patients with newly diagnosed MM who underwent the TD regimen as the initial therapy were analyzed retrospectively. The patients were divided into two groups according to the maximal sustained dose of Thal: lower dose (group A) and higher dose (group B). The overall response rate (ORR), progression free survival (PFS), overall survival (OS), and adverse events (AES) were compared between the two groups. Results: A total of 28 patients were followed up with a median of 18 months. The ORR was 60.1%. The median response time and PFS were 2.0 and 17.0 months, respectively. The mean sustained dose of Thal in group B was significantly higher than group A (292.9 mg v 180.4 mg, P=0.01). There was no significantly difference in ORR (57.1% v 64.3%, P=1.00) and PFS (9.63months v 17.66 months, P=0.73) between groups A and B. During the follow up, only five patients died (<40%) and, therefore, median OS values were not available. It is estimated, however, that the mean survival time in the two groups was 35.6 and 33.4 months (P>0.05), respectively. All of the patients tolerated the treatment well. The incidence of AES in patients with a grading above 3 in group B was significantly higher than in group A (P=0.033). Conclusions: The TD regimen results in a high response rate and manageable AES as the initial therapy in elderly patients with MM. TD should be considered as the front line regimen for the treatment of elderly patients with MM in areas with financial constraints. The clinical response can be achieved at a low dose Thal with minimal toxicity.